Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Barakaldo – page 11

205 clinical trials in Barakaldo, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Barakaldo at a glance
205
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

205 trials in Barakaldo

Open in trial search

Basal cell carcinoma

Not recruiting

A study to evaluate the safety and effectiveness of BO-112 injections in patients with resectable primary basal cell carcinoma.

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Polyinosinic:polycytidylic Acid
  • Sponsor:Highlight Therapeutics S.L.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Empagliflozin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Small cell lung cancer

Not recruiting

Study of Durvalumab for Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

COVID-19

Not recruiting

Study on the Safety and Immune Response of PHH-1V81 Booster for Adults Vaccinated Against COVID-19

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Raxtozinameran
  • Sponsor:Hipra Scientific S.L.

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Parkinson's disease

Not recruiting

Study of CVN424 for Reducing Motor Complications in Parkinson's Disease Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:1-[2-[4-(2,4-DIFLUOROPHENOXY)PIPERIDIN-1-YL]-3-[[(3R)-OXOLAN-3-YL]AMINO]-7,8-DIHYDRO-5H-PYRIDO[3,4-B]PYRAZIN-6-YL]ETHANONE
  • Sponsor:Cerevance Beta Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Benralizumab with Budesonide and Formoterol in Patients with Eosinophilic Asthma Uncontrolled by Standard Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Septic shock

Not recruiting

Study on Resuscitation in Early Septic Shock Using Sodium Chloride and a Drug Combination for Patients with Septic Shock

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Chloride
  • Sponsor:Pontificia Universidad Catolica de Chile

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barakaldo

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on acute cerebral ischemic stroke treatments and groundbreaking studies in Parkinson's disease management, including trials of novel compounds like NEU-411 and CVN424.

  • Stroke intervention studies
  • Early Parkinson's treatments
  • Neurological therapeutics

These trials aim to improve patient outcomes and develop more effective treatment strategies.

02 Oncology Research

Comprehensive cancer studies including treatments for metastatic prostate cancer, pancreatic adenocarcinoma, and innovative approaches in breast cancer therapy.

  • Prostate cancer treatments
  • Hepatic tumors
  • Breast cancer therapies

Focus on developing targeted therapies and improving survival rates across various cancer types.

03 Infectious Diseases

Studies addressing COVID-19 vaccination strategies and treatments for invasive candidiasis, with particular attention to antimicrobial therapies.

  • COVID-19 boosters
  • Fungal infections
  • Endocarditis treatments

These trials evaluate new therapeutic approaches and vaccine effectiveness.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.